Personalized, Risk-based Glycemic Control in the ICU

Glucomeo transforms insulin and nutrition therapy with tailored, risk-based clinical decision support, optimizing glucose control to improve patient outcomes, streamline nursing workflows, and significantly reduce costs.

Leveraging digital twins technology, Glucomeo identifies real-time, patient-specific insulin sensitivity and predicts individual responses to treatment—ensuring precise insulin and nutrition dosing.

Why Choose Glucomeo?

✅ Personalized Insulin Management: Tailors insulin delivery to each patient’s needs.
✅ Real-time Insights: Continuous monitoring for immediate adjustments.
✅ Improved Patient Outcomes: Achieve up to 80% time in target glucose range and reduce hypoglycemic risks.
✅ Efficiency & Cost Reduction: 36% reduction in protocol time and 30% workload reduction optimizing ICU resources.
✅ Seamless Integration with Nutromeo: Gain a complete view of the intricate balance between glycemia, nutrition, and insulin, ensuring optimal ICU patient management.

Clinical Results using Glucomeo™

📊 80% Efficacy:
High time in normoglycemic ranges associated with improved outcomes and reducing ICU length of stay.

🩸 0.004% Hypoglycemia:
Avoiding severe hypos and associated complications for stress-free control.

🍎️ 85% Nutrition Goal:
Ensure high nutritional intake while stabilizing glucose in target.

⏱️ 36% protocol time reduction:
High efficacy and saety from optimized control enables typical faster recovery.

📑 33% reduced workload :
Automatically adjust measurement intervals based on patient-specific risks of hyper- and hypo- glycemia.

🔄 20% reduced human errors:
thanks to automation, reminder, alarms, and real-time data monitoring.

* Publication links:
Stewart K. et al., Safety, efficacy and clinical generalization of the STAR protocol: a retrospective analysis, 2016.
Stewart K. et al., Nutrition delivery of a model-based ICU glycaemic control system, 2018.
Uyttendaele V. et al., Clinical trial validation of the STAR-3D glycemic control framework, 2023.

Who uses Glucomeo™?

Glucomeo™ has treated over 2500 adult ICU patients to date in 4 hopitals across the world:
- Christchurch, New Zealand (where it is now the standard of care)
- Liège, Belgium (where it will soon be the standard of care)
- Gyula, Hungary
- Kuantan, Malaysia

We are also currently undertaking clinical trials in Neonatal Intensive Care Units (NICU).

Want to use Glucomeo™ and be in the list? Happy to take part in our clinical trials? Flick us an email!

What Users Say

“We rely on Glucomeo and Nutromeo for all our ICU patients, giving us real-time insights into glycemia and nutritional status. This all-in-one solution helps us understand the complex relationship between glucose, insulin, and nutrition intake, leading to significantly improved patient outcomes and reduced care costs. Lives were saved thanks to personalized glucose control and nutrition therapy.”
– Dr. Geoff S., Head of ICU at Christchurch Hospital, New Zealand

"We believed our ICU had no issues with glucose control, until we took a closer look. We realized that, despite targeting higher conventional ranges, we were still experiencing excessive hypoglycemic events.
With Glucomeo, every patient now receives safe and effective glucose management, and adverse events are automatically reported and analyzed for continuous quality improvement."
– Dr. Balasz B., Gyula Hospital, Hungary

Experience the Future of Glucose Management

Get started with a double-click, no complex installation required! Compatible with Java 8 VM and modern browsers.